Prophage in Phage Manufacturing: Is the Risk Overrated Compared to Other Therapies or Food?
The rehabilitation of lytic bacteriophages, as living and replicative biological therapeutic agents, is only 2 decades old in western countries, compared to other therapeutic approaches using chemicals and inactivated or alive biologicals. This paper attempts to provide arguments to address prophage...
Main Author: | Gabard Jérôme |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/9/8/435 |
Similar Items
-
The heterogenous and diverse population of prophages in Mycobacterium genomes
by: Lawrence Abad, et al.
Published: (2023-10-01) -
Campylobacter prophage diversity reveals pervasive recombination between prophages from different Campylobacter species
by: Adán Manuel Piña-González, et al.
Published: (2024-01-01) -
In Silico Characterisation of Putative Prophages in <i>Lactobacillaceae</i> Used in Probiotics for Vaginal Health
by: Anna-Ursula Happel, et al.
Published: (2022-01-01) -
Whole-genome analysis showed the promotion of genetic diversity and coevolution in Staphylococcus aureus lytic bacteriophages and their hosts mediated by prophages via worldwide recombination events
by: Wenyuan Zhou, et al.
Published: (2023-03-01) -
Liposomal Delivery of Newly Identified Prophage Lysins in a <em>Pseudomonas aeruginosa</em> Model
by: Diana Morais, et al.
Published: (2022-09-01)